NDA 050689 · Pfizer
Mycobutin
Rifabutin · Oral · Rifamycin Antimycobacterial
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Dec 23, 1992
Approved uses
1
Original approval plus efficacy supplements
Registered trials
91
18 Phase 3, 5 recruiting
FAERS reports
2,755
2,287 serious, 310 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2026.
INDICATIONS AND USAGE Rifabutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
Mechanism: Mechanism of Action Rifabutin inhibits DNA-dependent RNA polymerase in susceptible strains of Escherichia coli and Bacillus subtilis but not in mammalian cells. In resistant strains of E. coli , rifabutin, like rifampin, did not inhibit this enzyme. It is not known whether rifabutin inhibits DNA-dependent RNA polymerase in Mycobacterium avium or in M. intracellulare which comprise M. avium complex (MAC).
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 1992 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- MYCOBUTIN · RIFABUTIN 150MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Rifabutin" as an intervention, any sponsor and status, largest first.
- The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected PatientsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00001030 · 1,100 participants
Drug: Clarithromycin; Rifabutin · For: Mycobacterium Avium-intracellulare Infection; HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Oakland, California · 42 sites in all
- Research on New Regimens for Retreatment Pulmonary TuberculosisPivotal-lookingStatus unknown
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT02331823 · 864 participants (planned) · Start Jun 2013 · Primary completion Dec 2015
Drug: Isoniazid Aminosalicylate Tablets; Streptomycin injectable · For: Reinfection Pulmonary Tuberculosis
Sites: Shanghai, China
PharmaciaPfizer (PFE)
NCT00002267 · 750 participants
Drug: Rifabutin · For: Mycobacterium Avium-intracellulare Infection; HIV Infections
Sites: Phoenix, Arizona; Berkeley, California; Beverly Hills, California · 43 sites in all
PharmaciaPfizer (PFE)
NCT00002032 · 750 participants
Drug: Rifabutin · For: Mycobacterium Avium-intracellulare Infection; HIV Infections
Sites: Irvine, California; Sylmar, California; Denver, Colorado · 33 sites in all
- A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected PatientsPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00002122 · 720 participants
Drug: Azithromycin; Rifabutin and 1 more · For: Mycoses; Mycobacterium Avium-Intracellulare Infection; HIV Infections
Sites: Los Angeles, California; Orange, California; San Diego, California · 12 sites in all
- ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active ComparatorPivotal-lookingCompleted
RedHill Biopharma LimitedIndustry
NCT03198507 · 455 participants · Start Jun 18, 2017 · Primary completion Oct 24, 2018
Drug: RHB-105; Active Comparator · For: Helicobacter Pylori Infection; Dyspepsia
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or PlaceboPivotal-lookingCompleted
PharmaciaPfizer (PFE)
NCT00002101 · 450 participants
Drug: Ethambutol hydrochloride; Clarithromycin and 1 more · For: Mycobacterium Avium-Intracellulare Infection; HIV Infections
Sites: Phoenix, Arizona; Harbor City, California; Irvine, California · 44 sites in all
- Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIRPivotal-lookingRecruiting
Tourcoing HospitalAcademic, hospital or other
NCT04672525 · 436 participants (planned) · Start Nov 8, 2021 · Primary completion Nov 2026
Drug: Rifabutin; Rifampicin · For: Prosthetic Infection
Sites: Amiens, France; Angers, France; Besançon, France · 30 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction270
- drug ineffective268
- off label use223
- nausea171
- pyrexia163
- drug resistance161
- mycobacterium avium complex infection150
- drug intolerance129
- neutropenia120
- immune reconstitution inflammatory syndrome119
- product use in unapproved indication109
- diarrhoea100
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 25 |
| 2005 | 25 |
| 2006 | 27 |
| 2007 | 27 |
| 2008 | 29 |
| 2009 | 59 |
| 2010 | 48 |
| 2011 | 59 |
| 2012 | 64 |
| 2013 | 42 |
| 2014 | 26 |
| 2015 | 64 |
| 2016 | 94 |
| 2017 | 99 |
| 2018 | 173 |
| 2019 | 135 |
| 2020 | 152 |
| 2021 | 168 |
| 2022 | 206 |
| 2023 | 297 |
| 2024 | 344 |
| 2025 | 390 |
| 2026 | 202 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mycobutin (Rifabutin)
2024 spending
$12K
Beneficiaries
16
17 claims
Per beneficiary
$721
$16.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $32,219 |
| 2021 | $89,640 |
| 2022 | $47,124 |
| 2023 | $19,148 |
| 2024 | $11,530 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management.
MacDougall C, Canonica T, Keh C, et al. · Pharmacotherapy 2022 · Systematic Review
- HIV: treating tuberculosis.
Payne B, Bellamy R · BMJ Clin Evid 2009 · Systematic Review
- Rifabutin for treating pulmonary tuberculosis.
Davies G, Cerri S, Richeldi L · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Clinical pharmacokinetics of potassium competitive acid blockers: a systematic review and meta-analysis.
Liu J, Hahn J · Front Pharmacol 2025 · Systematic Review
- Anti-tuberculous therapy for maintenance of remission in Crohn's disease.
Patton PH, Parker CE, MacDonald JK, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Systematic Review
- HIV: primary and secondary prophylaxis for opportunistic infections.
Aberg J, Powderly W · BMJ Clin Evid 2010 · Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.